Founded in 1994, Euroscreen SA is a clinical-stage, privately-held biotechnology company based in Belgium. Our mission is to invent and develop small-molecule drug candidates to valuable endpoints for licensing/partnering with pharmaceutical companies. Euroscreen's competitive advantage comes from our focus on GPCR drug targets and the proven efficiency of our integrated research team to deliver innovative drug candidates through to preclinical or early clinical endpoints attractive to big pharma partners.
Euroscreen is the leading company in the development of NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. Our drug candidate, ESN364, is in Phase IIa clinical trials during 2015/16, to continue to establish its superior safety profile, as well as clear demonstrations of the drug’s proof of concept in Poly-Cystic Ovary Syndrome (PCOS), uterine fibroids and menopausal hot flashes. Euroscreen has the expert support of its Clinical Advisory Board and the financial support from its investors to advance ESN364 in these multiple indications which will position us for a significant partnership of this program to both further grow the Company's position for a profitable exit for shareholders.
Euroscreen's portfolio also includes its patented program for the treatment of unmet medical needs, which was partnered with Merck Sharp & Dohm Corp. in November, 2014. We are also advancing a small-molecule, drug discovery program with ESN502, modulating a CNS target implicated in key neurological processes which are fundamental to neurodegenerative disorders such as Alzheimer's disease (AD). This target is predominantly expressed in the human brain where increased receptor expression has been observed in patients suffering from sporadic AD. Euroscreen is advancing this program internally with key proof of concept data in animal models and patent filings in 2015. The Company is mindful of the complexity and expense of developing therapeutics in the field of neurodegenerative disorders and is therefore open to near term partnering discussions with expert partners in the field.